3-Hydroxy-2-oxindole Derivatives Containing Sulfonamide Motif: Synthesis, Antiviral Activity, and Modes of Action.

J Agric Food Chem

State Key Laboratory Breeding Base of Green Pesticide and Agricultural Bioengineering, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Huaxi District, Guiyang 550025, China.

Published: January 2023


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

3-Hydroxy-2-oxindole motif constitutes a core structure in numerous natural products and imparts notable biological activities. Here, we describe the design and synthesis of four series of novel 3-substituted-3-hydroxy-2-oxindole derivatives containing sulfonamide moiety along with their antiviral activities against potato virus Y (PVY). Compound displayed optimal antiviral activity and superior anti-PVY activity compared with the lead compound and commercial Ningnanmycin in terms of curative and protective effects. Additionally, considerably inhibited PVY systemic infection in . Physiological and biochemical analyses revealed that the activities of the four crucial defense-related enzymes increased in the tobacco plant following treatment with . RNA-sequencing analysis revealed that substantially induced the upregulation of 38 differentially expressed genes, which were enriched in the photosynthesis pathway. These findings suggest that is a promising antiviral agrochemical that can effectively control PVY infection and trigger plant host immunity to develop virus resistance. This study provides novel molecular entities and ideas for developing new pesticides.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jafc.2c06881DOI Listing

Publication Analysis

Top Keywords

derivatives sulfonamide
8
antiviral activity
8
3-hydroxy-2-oxindole derivatives
4
sulfonamide motif
4
motif synthesis
4
antiviral
4
synthesis antiviral
4
activity modes
4
modes action
4
action 3-hydroxy-2-oxindole
4

Similar Publications

CYP72A15 confers resistance against penoxsulam to Echinochloa phyllopogon.

Pestic Biochem Physiol

November 2025

Shenyang Agricultural University, College of Plant Protection, Shenyang, Liaoning 110866, PR China. Electronic address:

As the weed Echinochloa phyllopogon has rapidly developed multi- and cross-resistance to several herbicides, we aimed to determine the mechanism underlying penoxsulam resistance in weeds. There was no target mutation in the tested population, and P450 enzyme activity was significantly higher in the penoxsulam-treated resistant population, confirming that non-target-site resistance was dominant. The antioxidant enzyme activity of the resistant population was higher than that of the sensitive population following the application of the penoxsulam and cleared HO faster.

View Article and Find Full Text PDF

Tilorone, a 9-fluorenone scaffold-based molecule, is a known broad-spectrum antiviral with an IC of 180 nM against SARS-CoV-2, but its mechanism is not known. In the present study, we found it to have weak activity against PLpro (IC = 30.7 ± 7.

View Article and Find Full Text PDF

Compounds that possess a benzene sulfonamide structure are utilized in a wide range of fields. Benzene bissulfonamides are also important compounds in the field of organic and medicinal chemistry. Based on these features, a series of benzene bissulfonamides were synthesized in moderate yields starting from 3-methylanisole.

View Article and Find Full Text PDF

Transcriptional enhanced associate domain (TEAD), overexpressed in hepatocellular carcinoma (HCC) and inversely correlated to prognosis, has emerged as a promising target for HCC therapy. To date, no small-molecule inhibitors targeting TEAD have been reported for HCC treatment. In this study, a bioinformatic analysis has been performed and has demonstrated that TEAD is a promising target for therapeutic intervention in HCC.

View Article and Find Full Text PDF

Direct-acting antivirals (DAAs) have transformed hepatitis C virus (HCV) treatment in Australia since their inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2016. Treatment has shifted from genotype-specific to pan-genotypic regimens, with glecaprevir/pibrentasvir and sofosbuvir/velpatasvir now recommended in clinical guidelines. This study examined trends in DAA dispensing in light of evolving treatment regimens.

View Article and Find Full Text PDF